MorphoSys

Tome Biosciences Launches with Over $200 Million in Funding to Advance Programmable Genomic Integration Platform

Retrieved on: 
Tuesday, December 12, 2023
Constellation, Entrepreneurship, Hospital, Genetic code, MIT, CMC, CRISPR, JD, PASTE, Brigham and Women's Hospital, DNA, MD, Doctor of Philosophy, Therapy, Investment, HR, Polaris Partners, Novo Nordisk, Novartis, Polaris, Patent, MorphoSys, Cas9, ARCH, ARCH Venture Partners, Gene expression, Bruker, Genetic heterogeneity, Gene, Merck, PGI, Genome, Enzyme, Fujifilm, Patient, GV, Intellia Therapeutics

Backed by leading biotech investors Andreessen Horowitz, ARCH, GV, Longwood, Polaris and others

Key Points: 
  • Backed by leading biotech investors Andreessen Horowitz, ARCH, GV, Longwood, Polaris and others
    WATERTOWN, Mass., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Tome Biosciences , Inc., the programmable genomic integration company, has launched to usher in a new era of genomic medicines based on programmable genomic integration (PGI).
  • “PGI represents the maturation of editing technologies, breaking current barriers in genomic medicines discovery,” said Rahul Kakkar, MD, President and Chief Executive Officer.
  • “PGI is revolutionary in that we can finally reprogram the human genome with an elegance and efficiency previously unimaginable.
  • Tome has an exclusive license to the core PASTE technology, which includes granted US patent numbers 11,572,556, 11,827,881 and 11,834,658.

MorphoSys’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study

Retrieved on: 
Monday, December 11, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Cough, FACP, Spleen, PST, Food, European Medicines Agency, JAK, GMT, ASH, Headache, Plasma, Disease, Constipation, IL-6, Fatigue, MorphoSys, Patient, Thrombocytopenia, CET, Periodic breathing, Weakness, COVID-19, Prognosis, Diarrhea, Nausea, Survival, EST, Dysgeusia, TNF, Anemia, Fibrosis, Ruxolitinib, BET, Bone marrow, Dizziness, Vaccine, Dietary supplement, Medical imaging

Average hemoglobin levels were greater in patients receiving pelabresib and ruxolitinib than in those receiving placebo plus ruxolitinib, starting at week 9 and continuing to week 24.

Key Points: 
  • Average hemoglobin levels were greater in patients receiving pelabresib and ruxolitinib than in those receiving placebo plus ruxolitinib, starting at week 9 and continuing to week 24.
  • Increased cytokine levels are associated with all four disease hallmarks; increased IL-8 levels are also associated with worse survival outcomes.
  • Discontinuation rates due to adverse events were 10.7% with pelabresib and ruxolitinib and 6.5% with placebo plus ruxolitinib.
  • “The four hallmarks of myelofibrosis – enlarged spleen, anemia, bone marrow fibrosis and disease-associated symptoms – have a strong impact on a patient’s life.

MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction

Retrieved on: 
Monday, November 20, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, FSE, Ruxolitinib, MorphoSys, Patient, TSS, BET, JAK, Pharmaceutical industry, Medical imaging

MANIFEST-2 met its primary endpoint, as the combination therapy demonstrated a statistically significant and clinically meaningful improvement in the proportion of patients achieving at least a 35% reduction in spleen volume (SVR35) at week 24.

Key Points: 
  • MANIFEST-2 met its primary endpoint, as the combination therapy demonstrated a statistically significant and clinically meaningful improvement in the proportion of patients achieving at least a 35% reduction in spleen volume (SVR35) at week 24.
  • The key secondary endpoints assessing symptom improvement – proportion of patients achieving at least a 50% reduction in total symptom score (TSS50) and absolute change in total symptom score (TSS) from baseline at week 24 – showed a strong positive trend favoring the pelabresib and ruxolitinib combination.
  • “Importantly, we saw significant symptom improvements for the vast majority of patients in the study.
  • “The pelabresib and ruxolitinib combination therapy significantly reduced spleen volume – the best prognostic indicator we have at our disposal for long-term myelofibrosis patient outcomes.

MorphoSys AG Reports First Nine Months and Third Quarter 2023 Financial Results

Retrieved on: 
Wednesday, November 15, 2023
Biotechnology, Pharmaceutical, Health, Oncology, FSE, EZH1, Annual general meeting, PST, Food, JAK, ASH, Patient, ARID1A, FDA, Abstract, EST, Society, Ruxolitinib, EZH2, Fast Track, BET, Pharmaceutical industry, Video game, Tafasitamab, MorphoSys

MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the third quarter and the first nine months of 2023.

Key Points: 
  • MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the third quarter and the first nine months of 2023.
  • “Sales of Monjuvi remain on track for its approved indication, allowing us to narrow our full-year 2023 guidance target.
  • Minjuvi royalty revenue of € 1.2 million for sales outside of the U.S. in the third quarter 2023 and € 4.1 million for the first nine months of 2023.
  • Events After the End of the Third Quarter of 2023:
    MorphoSys updated its financial guidance for 2023 financial year on October 25, 2023.

EQS-News: MorphoSys Places New Shares from Cash Capital Increase with Gross Proceeds of Approximately EUR 102.7 Million

Retrieved on: 
Thursday, December 14, 2023
XETRA, Financial services, Ruxolitinib, Relevance (Person of Interest), Frankfurt Stock Exchange, Regulation, Person, FSE, Wells Fargo, AMERICA, Qualification, Gross metropolitan product, Prospectus, Investment, EUR, Failure, MorphoSys, UBS, SEC Rule 144A, European Parliament, European Economic Area, Finance, BET, Council, Truist, Jefferies, Acquisition, EEA, Security (finance), Pharmaceutical industry, Order

The 3,423,194 new ordinary bearer shares with no-par value (Stückaktien) (“New Shares”) have been placed with institutional investors at a placement price of EUR 30.00 per new share by way of an accelerated bookbuilding, resulting in gross proceeds of approximately EUR 102.7 million.

Key Points: 
  • The 3,423,194 new ordinary bearer shares with no-par value (Stückaktien) (“New Shares”) have been placed with institutional investors at a placement price of EUR 30.00 per new share by way of an accelerated bookbuilding, resulting in gross proceeds of approximately EUR 102.7 million.
  • “MorphoSys’ oncology pipeline offers promising value-creating opportunities, with pelabresib, our investigational BET inhibitor, at the forefront,” said Jean-Paul Kress, M.D., Chief Executive Officer of MorphoSys.
  • “With pelabresib, we have the potential to shift the treatment paradigm in myelofibrosis, a field in dire need of innovation.
  • The placement price represents a discount of 2.8% compared to the 5-day volume-weighted average price (XETRA) of the Company’s shares.

EQS-News: MorphoSys AG Reports First Nine Months and Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, December 14, 2023
Annual general meeting, Food, Fast Track, Ruxolitinib, Conference call, BET, FSE, EZH2, CET, EZH1, JAK, Society, FDA, ASH, Abstract, PST, Patient, Conference, Webcast, ARID1A, Pharmaceutical industry, Cryptocurrency, Video game, Tafasitamab, MorphoSys

“With pelabresib, MorphoSys has the potential to meaningfully improve upon current first-line treatments for patients with myelofibrosis.

Key Points: 
  • “With pelabresib, MorphoSys has the potential to meaningfully improve upon current first-line treatments for patients with myelofibrosis.
  • Minjuvi royalty revenue of € 1.2 million for sales outside of the U.S. in the third quarter 2023 and € 4.1 million for the first nine months of 2023.
  • Events After the End of the Third Quarter of 2023:
    MorphoSys updated its financial guidance for 2023 financial year on October 25, 2023.
  • Total revenues for the third quarter 2023 were € 63.8 million compared to € 95.8 million for the same period in 2022.

EQS-News: Invitation to MorphoSys’ Third Quarter and First Nine Months 2023 Financial Results Conference Call on November 16, 2023

Retrieved on: 
Sunday, December 10, 2023
Management, Conference, EST, Q&A, GMT, FSE, MorphoSys, CET, Webcast, Clothing, Flour, Video game

Invitation to MorphoSys’ Third Quarter and First Nine Months 2023 Financial Results Conference Call on November 16, 2023

Key Points: 
  • Invitation to MorphoSys’ Third Quarter and First Nine Months 2023 Financial Results Conference Call on November 16, 2023
    The issuer is solely responsible for the content of this announcement.
  • Invitation to MorphoSys’ Third Quarter and First Nine Months 2023 Financial Results Conference Call on November 16, 2023
    MorphoSys AG (FSE: MOR; NASDAQ: MOR) will publish its results for the third quarter and first nine months 2023 on November 15, 2023, at 10:00 pm CET (09:00 pm GMT; 04:00 pm EST).
  • MorphoSys' Management team will host a conference call and webcast on November 16, 2023, at 02:00 pm CET (01:00 pm GMT; 08:00 am EST) to present the results for the third quarter and first nine months 2023 and provide an outlook for the remainder of the year.
  • The conference call will start with a presentation by the Management team followed by a Q&A session.

Xencor Sells Portion of Royalties and Milestones from Ultomiris® and Monjuvi® to OMERS Life Sciences for $215 Million

Retrieved on: 
Tuesday, November 7, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Sale, Tafasitamab, MorphoSys, Protein engineering, Cytokine, Alexion Pharmaceuticals, Antibody, Cancer, OMERS, Ravulizumab

Under the agreements, Xencor has received a $215 million payment from OMERS.

Key Points: 
  • Under the agreements, Xencor has received a $215 million payment from OMERS.
  • OMERS has acquired royalties due to Xencor on global Ultomiris sales from July 1, 2023 onward, with annual caps beginning in 2026, and the majority of a milestone payment earned this year.
  • Xencor will also be eligible for a new Ultomiris sales-based milestone payment from OMERS.
  • OMERS has also acquired royalties on global Monjuvi sales from July 1, 2023 until OMERS has received 1.3 times the value of the Monjuvi purchase price.

Xencor Reports Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, November 7, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, CLDN3, Ovarian cancer, CD28, Telephone, STEAP1, OMERS, CLDN4, Sale, Vir, ESMO, Amgen, Cytokine, Gilead Sciences, Antibody, Part, Safety, Cancer, Investment, Patient, Congress, G&A, Prostate cancer, CTA, ENPP3, CLDN6, Liver disease, Genentech, European Society for Medical Oncology, CLDN9, Tafasitamab, IND, CD3, Colorectal cancer, R, Environment, Ravulizumab, Lung cancer, PARP, Vaccine, Pharmaceutical industry, Medical imaging, Rare-earth element, Cryptocurrency, Omeros, Janssen, MorphoSys, Alexion, Astellas Pharma

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today reported financial results for the third quarter ended September 30, 2023 and provided a review of recent business and clinical highlights.

Key Points: 
  • Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today reported financial results for the third quarter ended September 30, 2023 and provided a review of recent business and clinical highlights.
  • Total revenue for the third quarter ended September 30, 2023 was $59.2 million, compared to $27.3 million for the same period in 2022.
  • Decreased net loss in the third quarter of 2023 compared to 2022 is primarily due to additional income earned.
  • ET (1:30 p.m. PT) to discuss the third quarter 2023 financial results and provide a corporate update.

EQS-News: MorphoSys To Showcase Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2023 ASH Annual Meeting

Retrieved on: 
Tuesday, November 7, 2023
Standard of care, Primary myelofibrosis, Progression-free survival, 65th United States Congress, Ruxolitinib, Research, JAK, Society, Abstract (summary), ASH, Clinical trial, Abstract, FSE, Tafasitamab, BET, Exposition, Patient, TSS, Joint Planning and Development Office, Pharmaceutical industry, Book, MorphoSys

The conference is being held in San Diego, California, from December 9 to 12, 2023.

Key Points: 
  • The conference is being held in San Diego, California, from December 9 to 12, 2023.
  • “We will be sharing topline results from our pivotal MANIFEST-2 study in the coming weeks and look forward to presenting detailed findings at ASH 2023 shortly thereafter.
  • A total of 431 patients were randomized in the study, making it one of the largest myelofibrosis studies conducted to date.
  • One additional abstract on pelabresib and six abstracts on tafasitamab, marketed in the U.S. as Monjuvi® and outside the U.S. by Incyte as Minjuvi®, were accepted for presentation and publication at ASH 2023.